All data are based on the daily closing price as of April 10, 2026
m
Medy-Tox
086900.KQ
68.70 USD
-1.96
-2.77%
Overview
Last close
68.70 usd
Market cap
451.98M usd
52 week high
140.02 usd
52 week low
64.86 usd
Target price
85.7 usd
Valuation
P/E
N/A
Forward P/E
31.25
Price/Sales
2.7109
Price/Book Value
1.4844
Enterprise Value
470.29M usd
EV/Revenue
2.8237
EV/EBITDA
25.579
Key financials
Revenue TTM
166.55M usd
Gross Profit TTM
96.20M usd
EBITDA TTM
24.75M usd
Earnings per Share
N/A usd
Dividend
3.23 usd
Total assets
403.24M usd
Net debt
17.83M usd
About
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.